Martin Richman, MD
Urology · Safety Harbor, FLNPI 1659363851
Payments from drug & device makers
Across 154 payments — averaging $106.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$4K
- Avyxa Pharma, LLC$3K
- Verathon Inc.$2K
- Boston Scientific$2K
- Lumenis, Inc$2K
- Procept Biorobotics Corporation$1K
- plus $3K from 35 others
What the payments were for
- Consulting fees$3,70023%
- Speaking & faculty fees$6,72041%
- Travel & lodging$1,5369%
- Food & beverage$4,29626%
- Education$1641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 5 | $3,587 |
| Avyxa Pharma, LLC | 6 | $3,106 |
| Verathon Inc. | 1 | $2,200 |
| Boston Scientific | 9 | $2,039 |
| Lumenis, Inc | 1 | $1,500 |
| Procept Biorobotics Corporation | 12 | $1,098 |
| Astellas Pharma US Inc | 10 | $310 |
| Medtronic | 2 | $299 |
| Sumitomo Pharma America, Inc. | 9 | $218 |
| Antares Pharma, Inc. | 28 | $209 |
| Telix Pharmaceuticals | 5 | $204 |
| Dendreon Pharmaceuticals LLC | 1 | $196 |
| AbbVie(2 entities) | 7 | $145 |
| Urogen Pharma, Inc. | 7 | $134 |
| Olympus America Inc. | 3 | $130 |
| Pharmaessentia USA Corporation | 1 | $115 |
| Teleflex LLC | 1 | $77 |
| Pfizer | 4 | $74 |
| Endo USA, Inc. | 3 | $71 |
| Axonics, Inc. | 1 | $63 |
| Coloplast | 3 | $61 |
| AstraZeneca | 2 | $60 |
| Novartis | 2 | $58 |
| Johnson & Johnson | 3 | $57 |
| Endo Pharmaceuticals Inc. | 3 | $54 |
| Bluewind Medical | 1 | $47 |
| Calyxo, Inc. | 2 | $39 |
| Bayer | 2 | $38 |
| Myriad Genetic Laboratories, Inc. | 2 | $37 |
| Verity Pharmaceuticals Inc. | 2 | $33 |
| Myovant Sciences Inc. | 1 | $20 |
| Bioprotect Medical, Inc. | 1 | $19 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Dentsply IH Inc. | 1 | $19 |
| Angiodynamics, Inc. | 1 | $18 |
| Neotract Inc. | 1 | $18 |
| Scynexis, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Metuchen Pharmaceuticals | 1 | $14 |
| SN Holdings, LLC | 5 | $0 |
| Urogpo LLC | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$3,345
- NPD Clinical Study$2,200
- GENERAL KIDNEY STONE DISEASE$1,630
- Lumenis Pulse 120H$1,500
- AquaBeam Robotic System$530
- INTERSTIM$299
- GENERAL - THERAPIES$253
- ILLUCCIX$231
- PROVENGE$196
- AQUABEAM SYSTEM$164
- BESREMI$115
How this compares
$16,415 in reported general payments places this provider in the 80th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 203 | $225,031 |
| GemtesaVibegron | 135 | $90,617 |
| XyostedTestosterone Enanthate | 28 | $16,734 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 470 | $10,413 |
| Mirabegron ErMirabegron | 25 | $9,985 |
| PremarinEstrogens, Conjugated | 22 | $9,528 |
| Tamsulosin Hcl | 657 | $9,442 |
| Finasteride | 380 | $4,569 |
| Testosterone Cypionate | 69 | $3,970 |
| Methenamine Hippurate | 36 | $3,226 |
| Estradiol | 47 | $2,926 |
| Cephalexin | 208 | $1,921 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,816 |
| Solifenacin Succinate | 63 | $1,768 |
| Dutasteride | 43 | $1,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $310 | $225,031203 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $218 | $90,617135 claims |
| Antares Pharma, Inc.Xyosted | $209 | $16,73428 claims |
| PfizerPremarin | $74 | $9,52822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 urology providers in Florida.
Other urology in Safety Harbor
- James ZacharySafety Harbor$344K
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.